STK11 and non-small cell lung carcinoma: STK11/LKB1- or KEAP1-mutated NSCLC patients had a higher bTMB than wild-type patients, and KEAP1-mutated patients had a higher PD-L1 expression (TC ≥ 50%/IC ≥ 50%: 25.00% vs. 14.54%), while STK11/LKB1-mutated patients had lower PD-L1 expression (TC ≥ 50%/IC ≥ 50%: 7.89% vs. 15.90%) [136].